GLP1R and colorectal cancer: Similarly, a study by Wang et al., which focused on overweight and obese drug-naïve patients initiating antidiabetic therapy, found that GLP-1 RA were associated with a 50% lower risk of colorectal cancer compared to insulin, and a 42% lower risk compared to metformin during a median follow-up of 3 years [15].